



Clinical trial results:

An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis

Summary

EudraCT number	2015-003261-28
Trial protocol	DE GB PT
Global end of trial date	01 November 2022

Results information

Result version number	v1 (current)
This version publication date	26 March 2025
First version publication date	26 March 2025

Trial information

Trial identification

Sponsor protocol code	CLN-PRO-V006
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02644941
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Humacyte, Inc.
Sponsor organisation address	2525 East NC Highway 54, Durham, United States, NC 27713
Public contact	Humacyte Clinical Development, Humacyte, Inc., +01 919 313 9633, hamel@humacyte.com
Scientific contact	Humacyte Clinical Development, Humacyte, Inc., +01 919 313 9633, hamel@humacyte.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 October 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 November 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the Secondary Patency of the human acellular vessel (HAV) with that of the expanded polytetrafluoroethylene (ePTFE) graft when used as a conduit for hemodialysis.

Protection of trial subjects:

The trial was designed and monitored in compliance with the ethical principles of Good Clinical Practice and consistent with the principles of the Declaration of Helsinki.

During the study, subjects were closely monitored.

After review of the investigator, the subjects' screening case report forms were also provided to the medical monitor for review and confirmation of eligibility before randomization. Randomization only occurred once the arterial and venous exposures had been completed with confirmation of adequate arterial inflow and venous outflow. During implantation, subjects received at least 1 dose of antibiotic prophylaxis, as well as antithrombotic prophylaxis in conjunction with graft implantation. The conduit's suitability for dialysis was evaluated by the surgeon at least 28 days post implantation.

Subjects were being followed at routine visits for at least 24 months post implantation regardless of their conduit's patency status.

In addition, a data monitoring committee was established to review safety on an ongoing basis and to provide recommendations about stopping, continuing or otherwise modifying the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 May 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 80
Country: Number of subjects enrolled	Portugal: 12
Country: Number of subjects enrolled	United Kingdom: 28
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	United States: 206
Country: Number of subjects enrolled	Israel: 26
Worldwide total number of subjects	355
EEA total number of subjects	95

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	191
From 65 to 84 years	156
85 years and over	8

Subject disposition

Recruitment

Recruitment details:

This was a large multicenter comparative study conducted at 37 centers in 6 countries to compare the HAV and ePTFE.

Pre-assignment

Screening details:

Subjects who met all inclusion criteria and none of the exclusion criteria were eligible to participate in the study. Eligibility was confirmed by the investigator and the medical monitor before randomization.

Period 1

Period 1 title	Up to Month 60 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Human acellular vessel

Arm description:

Subjects received a HAV and were initially followed up to Month 24. Subjects with a patent HAV at Month 24 were followed up to Month 60.

Arm type	Experimental
Investigational medicinal product name	Human acellular vessel
Investigational medicinal product code	HAV
Other name	Acellular tissue engineering vessel (ATEV)
Pharmaceutical forms	Implant
Routes of administration	Implantation

Dosage and administration details:

HAV is a tissue-engineered vascular conduit for hemodialysis access. The HAV is 6 mm in diameter and approximately 42 cm in length. The HAV was implanted using standard vascular surgical techniques similar to placement of synthetic or biologic arterio-venous grafts.

Arm title	ePTFE graft
------------------	-------------

Arm description:

The comparator is one of two commercially available 6 mm ePTFE graft (Bard Impira or Gore PROPATEN). Please note although not represented in the provided text both have the required trademark. Subjects were initially followed for 24 months. Subjects with a patent ePTFE graft at Month 24 were followed up to Month 60.

Arm type	Active comparator
Investigational medicinal product name	ePTFE graft
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Implantation

Dosage and administration details:

The ePTFE grafts are 6 mm in diameter and 40 cm in length. Implantation of the comparator grafts followed standard vascular surgical techniques.

Number of subjects in period 1	Human acellular vessel	ePTFE graft
Started	177	178
Completed Month 24	108	106
Continued follow-up to Month 60	78	80
Completed	42	39
Not completed	135	139
Consent withdrawn by subject	16	23
Adverse event, non-fatal	2	1
Death	65	65
Other	5	5
Abandoned study conduit	3	2
Did not continue follow-up to Month 60	30	26
Subject non-compliant	1	3
Lost to follow-up	11	12
Study conduit removal	2	2

Baseline characteristics

Reporting groups

Reporting group title	Human acellular vessel
-----------------------	------------------------

Reporting group description:

Subjects received a HAV and were initially followed up to Month 24. Subjects with a patent HAV at Month 24 were followed up to Month 60.

Reporting group title	ePTFE graft
-----------------------	-------------

Reporting group description:

The comparator is one of two commercially available 6 mm ePTFE graft (Bard Impira or Gore PROPATEN). Please note although not represented in the provided text both have the required trademark. Subjects were initially followed for 24 months. Subjects with a patent ePTFE graft at Month 24 were followed up to Month 60.

Reporting group values	Human acellular vessel	ePTFE graft	Total
Number of subjects	177	178	355
Age categorical			
Units: Subjects			
18-21 years	0	1	1
22-44 years	21	22	43
45-64 years	69	78	147
65-74 years	57	50	107
75 years and above	30	27	57
Age continuous			
Units: years			
median	64.0	60.0	
full range (min-max)	26 to 88	19 to 86	-
Gender categorical			
Units: Subjects			
Female	89	90	179
Male	88	88	176

End points

End points reporting groups

Reporting group title	Human acellular vessel
Reporting group description: Subjects received a HAV and were initially followed up to Month 24. Subjects with a patent HAV at Month 24 were followed up to Month 60.	
Reporting group title	ePTFE graft
Reporting group description: The comparator is one of two commercially available 6 mm ePTFE graft (Bard Impyra or Gore PROPATEN). Please note although not represented in the provided text both have the required trademark. Subjects were initially followed for 24 months. Subjects with a patent ePTFE graft at Month 24 were followed up to Month 60.	

Primary: Number of participants with loss of secondary patency

End point title	Number of participants with loss of secondary patency
End point description: Time to loss of secondary patency was defined as the interval from the time of access placement until access abandonment, with or without interventions. If a subject had a patent study conduit at the time of death, kidney transplant or withdrawal, time to loss of secondary patency was censored at that time point. Subjects who were lost to follow-up were censored at their last visit when it was known that the study conduit was patent. Subjects who were lost to follow-up and whose study conduit was not patent at the last completed visit were treated as abandoned at the time of study conduit occlusion. For subjects who remained in the study without meeting criteria for the event at the data cut-off, the time-to-event was censored and defined as the number of days from access placement to the data cut-off.	
End point type	Primary
End point timeframe: From the time of access placement until access abandonment assessed at Month 12, Month 18 and Month 24.	

End point values	Human acellular vessel	ePTFE graft		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	177	178		
Units: Subjects				
Number of patency losses at 12 months	29	34		
Number of patency losses at 18 months	41	38		
Number of patency losses at 24 months	48	41		

Statistical analyses

Statistical analysis title	Non-inferiority of secondary patency rates at M12
Statistical analysis description: Non-inferiority of secondary patency (even-free) rates were analysed using a binary non-inferiority analysis with a 10% non-inferiority margin. In the primary analysis, the while-on-treatment strategy was applied to unrelated intercurrents events; related intercurrents events were counted as secondary patency failures.	
Comparison groups	Human acellular vessel v ePTFE graft

Number of subjects included in analysis	355
Analysis specification	Post-hoc
Analysis type	non-inferiority ^[1]
P-value	= 0.0011 ^[2]
Method	Wilson (Score) test, 1-sided
Parameter estimate	Rate difference [%] (HAV - ePTFE)
Point estimate	2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.4
upper limit	10.8

Notes:

[1] - Non-inferiority with 10% margin.

Event-free rates [%] (n/N)

HAV 83.6% (148/177)

ePTFE 80.9% (144/178)

[2] - Based on a non-inferiority margin of 10%, the p-value is calculated from one-sided non-inferiority test at 2.5% level of significance. If the p-value is < 0.025, then non-inferiority is demonstrated (success).

Statistical analysis title	Non-inferiority of secondary patency rates at M18
-----------------------------------	---

Statistical analysis description:

Non-inferiority of secondary patency (even-free) rates were analysed using a binary non-inferiority analysis with a 10% non-inferiority margin. In the primary analysis, the while-on-treatment strategy was applied to unrelated intercurrents events; related intercurrents events were counted as secondary patency failures.

Comparison groups	Human acellular vessel v ePTFE graft
Number of subjects included in analysis	355
Analysis specification	Post-hoc
Analysis type	non-inferiority ^[3]
P-value	= 0.0323 ^[4]
Method	Wilson (Score) test, 1-sided
Parameter estimate	Rate difference [%] (HAV - ePTFE)
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	6.9

Notes:

[3] - Non-inferiority with 10% margin.

Event-free rates [%] (n/N)

HAV 76.8% (136/177)

ePTFE 78.7% (140/178)

[4] - Based on a non-inferiority margin of 10%, the p-value is calculated from one-sided non-inferiority test at 2.5% level of significance. If the p-value is < 0.025, then non-inferiority is demonstrated (success).

Statistical analysis title	Non-inferiority of secondary patency rates at M24
-----------------------------------	---

Statistical analysis description:

Non-inferiority of secondary patency (even-free) rates were analysed using a binary non-inferiority analysis with a 10% non-inferiority margin. In the primary analysis, the while-on-treatment strategy was applied to unrelated intercurrents events; related intercurrents events were counted as secondary patency failures.

Comparison groups	Human acellular vessel v ePTFE graft
-------------------	--------------------------------------

Number of subjects included in analysis	355
Analysis specification	Post-hoc
Analysis type	non-inferiority ^[5]
P-value	= 0.099 ^[6]
Method	Wilson (Score) test, 1-sided
Parameter estimate	Rate difference [%] (HAV - ePTFE)
Point estimate	-4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.1
upper limit	4.9

Notes:

[5] - Non-inferiority with 10% margin.

Event-free rates [%] (n/N)

HAV 72.9% (129/177)

ePTFE 77.0% (137/178)

[6] - Based on a non-inferiority margin of 10%, the p-value is calculated from one-sided non-inferiority test at 2.5% level of significance. If the p-value is < 0.025, then non-inferiority is demonstrated (success).

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events (AEs) were collected beginning at the time of study conduit implantation up to Month 24. After Month 24, only events of special interest and serious AEs (SAEs) related to the HAV were reported by the investigator.

Adverse event reporting additional description:

The total number of subjects affected by non-serious adverse events includes all subjects with at least 1 non-serious adverse event.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	Human acellular vessel (HAV)
-----------------------	------------------------------

Reporting group description:

Subjects received a HAV and were initially followed up to Month 24. Subjects with a patent HAV at Month 24 were followed up to Month 60.

Reporting group title	ePTFE graft
-----------------------	-------------

Reporting group description:

Subjects received one of two ePTFE grafts: the Gore PROPATEN Vascular Graft or Bard Impra Vascular Graft.

Serious adverse events	Human acellular vessel (HAV)	ePTFE graft	
Total subjects affected by serious adverse events			
subjects affected / exposed	157 / 177 (88.70%)	146 / 178 (82.02%)	
number of deaths (all causes)	68	65	
number of deaths resulting from adverse events	46	39	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Breast cancer			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic myelomonocytic leukaemia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aneurysm			
subjects affected / exposed	3 / 177 (1.69%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	2 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brachiocephalic vein occlusion			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brachiocephalic vein stenosis			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brachiocephalic vein thrombosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0
Deep vein thrombosis		
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Dry gangrene		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Haematoma		
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Haemorrhage		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypertension		
subjects affected / exposed	4 / 177 (2.26%)	8 / 178 (4.49%)
occurrences causally related to treatment / all	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0
Hypertensive crisis		
subjects affected / exposed	4 / 177 (2.26%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Hypertensive emergency		
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Hypotension		

subjects affected / exposed	10 / 177 (5.65%)	4 / 178 (2.25%)
occurrences causally related to treatment / all	0 / 10	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0
Jugular vein thrombosis		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral artery stenosis		
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral artery thrombosis		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral ischaemia		
subjects affected / exposed	0 / 177 (0.00%)	4 / 178 (2.25%)
occurrences causally related to treatment / all	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Shock		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Shock haemorrhagic		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Steal syndrome		
subjects affected / exposed	5 / 177 (2.82%)	6 / 178 (3.37%)
occurrences causally related to treatment / all	3 / 6	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0
Subclavian vein occlusion		

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian vein stenosis			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stenosis			
subjects affected / exposed	53 / 177 (29.94%)	49 / 178 (27.53%)	
occurrences causally related to treatment / all	178 / 182	132 / 140	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous haemorrhage			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous occlusion			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous stenosis			
subjects affected / exposed	7 / 177 (3.95%)	9 / 178 (5.06%)	
occurrences causally related to treatment / all	4 / 8	3 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			

subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	7 / 177 (3.95%)	5 / 178 (2.81%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 7	0 / 5	
Fatigue			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypothermia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site extravasation			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site necrosis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site paraesthesia			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Implant site ulcer		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Incarcerated hernia		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Inflammation		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza like illness		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Multiple organ dysfunction syndrome		
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1
Non-cardiac chest pain		
subjects affected / exposed	2 / 177 (1.13%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Pyrexia		
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Stent-graft endoleak		

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic allograft nephropathy			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contrast media reaction			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Breast haematoma			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	7 / 177 (3.95%)	4 / 178 (2.25%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Aspiration			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			

subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hypoxia		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Lung infiltration		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pleural effusion		
subjects affected / exposed	2 / 177 (1.13%)	4 / 178 (2.25%)
occurrences causally related to treatment / all	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia aspiration		
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Pulmonary congestion		
subjects affected / exposed	2 / 177 (1.13%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Pulmonary embolism		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pulmonary oedema		
subjects affected / exposed	4 / 177 (2.26%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Pulmonary vasculitis		

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory disorder			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	4 / 177 (2.26%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal stenosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	5 / 177 (2.82%)	4 / 178 (2.25%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device dislocation			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device end of service			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device expulsion			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Anticoagulation drug level below therapeutic			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial test positive			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Oxygen saturation decreased subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Anastomotic stenosis subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula maturation failure			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dialysis disequilibrium syndrome subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eschar subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Fall			
subjects affected / exposed	0 / 177 (0.00%)	4 / 178 (2.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodialysis complication			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodialysis-induced symptom			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional medical device removal by patient			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Laceration		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pelvic fracture		
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Post procedural complication		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Post procedural haemorrhage		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Procedural anxiety		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Procedural hypotension		
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Radius fracture		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Rib fracture		

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access complication			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access malfunction			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site bruising			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site haematoma			

subjects affected / exposed	3 / 177 (1.69%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	1 / 3	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site haemorrhage			
subjects affected / exposed	6 / 177 (3.39%)	8 / 178 (4.49%)	
occurrences causally related to treatment / all	3 / 7	8 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site occlusion			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site pain			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site pseudoaneurysm			
subjects affected / exposed	17 / 177 (9.60%)	5 / 178 (2.81%)	
occurrences causally related to treatment / all	22 / 23	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site rupture			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site swelling			
subjects affected / exposed	3 / 177 (1.69%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site thrombosis			
subjects affected / exposed	81 / 177 (45.76%)	57 / 178 (32.02%)	
occurrences causally related to treatment / all	182 / 198	138 / 160	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site vesicles			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous injury			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound haemorrhage			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			

subjects affected / exposed	8 / 177 (4.52%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 11	0 / 5
deaths causally related to treatment / all	0 / 3	0 / 1
Angina pectoris		
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Aortic valve stenosis		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Arrhythmia		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Arteriosclerosis coronary artery		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial fibrillation		
subjects affected / exposed	3 / 177 (1.69%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial flutter		
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Atrioventricular block		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Bradycardia		

subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	6 / 177 (3.39%)	11 / 178 (6.18%)	
occurrences causally related to treatment / all	0 / 6	0 / 11	
deaths causally related to treatment / all	0 / 3	0 / 9	
Cardiac failure			
subjects affected / exposed	4 / 177 (2.26%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 4	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	0 / 177 (0.00%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure congestive			
subjects affected / exposed	6 / 177 (3.39%)	8 / 178 (4.49%)	
occurrences causally related to treatment / all	0 / 8	0 / 11	
deaths causally related to treatment / all	0 / 2	0 / 1	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular insufficiency			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery disease			
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery stenosis			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Left ventricular failure		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Myocardial infarction		
subjects affected / exposed	4 / 177 (2.26%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 2
Myocardial ischaemia		
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Palpitations		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pulseless electrical activity		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Sinus node dysfunction		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Supraventricular tachycardia		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Tachycardia		

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nervous system disorders			
Carotid artery stenosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Cerebrovascular disorder			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic hyperosmolar coma			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic stroke			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Encephalopathy		
subjects affected / exposed	3 / 177 (1.69%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Epilepsy		
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Facial paralysis		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Headache		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hemiparesis		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypertensive encephalopathy		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hypoaesthesia		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy		

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Ischaemic stroke		
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0
Jugular vein occlusion		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Metabolic encephalopathy		
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Paresthesia		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral sensory neuropathy		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Presyncope		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Ruptured cerebral aneurysm		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Seizure		

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	4 / 177 (2.26%)	4 / 178 (2.25%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic outlet syndrome			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	7 / 177 (3.95%)	10 / 178 (5.62%)	
occurrences causally related to treatment / all	0 / 7	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Corneal erosion			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			

subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis haemorrhagic			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	5 / 177 (2.82%)	5 / 178 (2.81%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal necrosis			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Large intestinal stenosis			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Large intestine polyp		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Lower gastrointestinal haemorrhage		
subjects affected / exposed	0 / 177 (0.00%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Mouth haemorrhage		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Nausea		
subjects affected / exposed	0 / 177 (0.00%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Oesophageal mucosal hyperplasia		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Oesophagitis		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatitis acute		
subjects affected / exposed	0 / 177 (0.00%)	4 / 178 (2.25%)
occurrences causally related to treatment / all	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Rectal haemorrhage		

subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal ulcer			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux gastritis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary dyskinesia			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatitis alcoholic			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic angioedema			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic skin ulcer			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin erosion			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	4 / 177 (2.26%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	4 / 177 (2.26%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
End stage renal disease			
subjects affected / exposed	0 / 177 (0.00%)	5 / 178 (2.81%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haematuria			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephric collection			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Renal impairment			
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Androgen deficiency			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Back pain			
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture pain			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle necrosis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acanthamoeba infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Appendicitis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BK virus infection			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Bacteraemia		
subjects affected / exposed	0 / 177 (0.00%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Bronchitis		
subjects affected / exposed	3 / 177 (1.69%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Bronchitis bacterial		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Candida infection		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Catheter site infection		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Cellulitis		
subjects affected / exposed	1 / 177 (0.56%)	6 / 178 (3.37%)
occurrences causally related to treatment / all	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 1
Clostridium difficile colitis		
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Clostridium difficile infection		

subjects affected / exposed	3 / 177 (1.69%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coccidioidomycosis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus colitis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus viraemia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis viral			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	3 / 177 (1.69%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Enterobacter bacteraemia			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr viraemia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungaemia			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			

subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis shigella			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 177 (0.56%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster meningoencephalitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Implant site cellulitis			

subjects affected / exposed	0 / 177 (0.00%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective tenosynovitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	4 / 177 (2.26%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			

subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningoencephalitis amoebic			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising soft tissue infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	2 / 177 (1.13%)	6 / 178 (3.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal abscess			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			

subjects affected / exposed	3 / 177 (1.69%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peritonitis bacterial		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia		
subjects affected / exposed	11 / 177 (6.21%)	18 / 178 (10.11%)
occurrences causally related to treatment / all	0 / 17	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 1
Pneumonia bacterial		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia respiratory syncytial viral		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia viral		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Postoperative wound infection		
subjects affected / exposed	2 / 177 (1.13%)	3 / 178 (1.69%)
occurrences causally related to treatment / all	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Pseudomonal bacteraemia		

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Pyelonephritis		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory syncytial virus infection		
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection		
subjects affected / exposed	2 / 177 (1.13%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection viral		
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Sepsis		
subjects affected / exposed	13 / 177 (7.34%)	12 / 178 (6.74%)
occurrences causally related to treatment / all	2 / 14	1 / 12
deaths causally related to treatment / all	0 / 4	0 / 4
Septic shock		
subjects affected / exposed	4 / 177 (2.26%)	2 / 178 (1.12%)
occurrences causally related to treatment / all	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 3	0 / 0
Sialoadenitis		
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Skin infection		

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 177 (0.00%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	3 / 177 (1.69%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Streptococcal bacteraemia			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant abscess			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	2 / 177 (1.13%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal infection			

subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site infection			
subjects affected / exposed	13 / 177 (7.34%)	18 / 178 (10.11%)	
occurrences causally related to treatment / all	3 / 14	15 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound sepsis			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Calciphylaxis			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes with hyperosmolarity			

subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 177 (0.56%)	3 / 178 (1.69%)	
occurrences causally related to treatment / all	0 / 1	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	7 / 177 (3.95%)	8 / 178 (4.49%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	3 / 177 (1.69%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	9 / 177 (5.08%)	9 / 178 (5.06%)	
occurrences causally related to treatment / all	0 / 15	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hypervolaemia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochloraemia			
subjects affected / exposed	1 / 177 (0.56%)	0 / 178 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			

subjects affected / exposed	0 / 177 (0.00%)	4 / 178 (2.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 177 (0.00%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	2 / 177 (1.13%)	2 / 178 (1.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	1 / 177 (0.56%)	1 / 178 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Human acellular vessel (HAV)	ePTFE graft	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	165 / 177 (93.22%)	163 / 178 (91.57%)	
Injury, poisoning and procedural complications			
Vascular access site complication			
subjects affected / exposed	9 / 177 (5.08%)	7 / 178 (3.93%)	
occurrences (all)	9	7	
Vascular access site haematoma			
subjects affected / exposed	47 / 177 (26.55%)	34 / 178 (19.10%)	
occurrences (all)	62	39	
Vascular access site haemorrhage			
subjects affected / exposed	39 / 177 (22.03%)	28 / 178 (15.73%)	
occurrences (all)	53	37	
Vascular access site oedema			
subjects affected / exposed	9 / 177 (5.08%)	9 / 178 (5.06%)	
occurrences (all)	9	9	

Vascular access site pain subjects affected / exposed occurrences (all)	12 / 177 (6.78%) 13	17 / 178 (9.55%) 20	
Vascular access site pseudoaneurysm subjects affected / exposed occurrences (all)	62 / 177 (35.03%) 91	38 / 178 (21.35%) 55	
Vascular access site swelling subjects affected / exposed occurrences (all)	26 / 177 (14.69%) 30	20 / 178 (11.24%) 21	
Vascular access site thrombosis subjects affected / exposed occurrences (all)	79 / 177 (44.63%) 276	55 / 178 (30.90%) 120	
Wound dehiscence subjects affected / exposed occurrences (all)	9 / 177 (5.08%) 9	3 / 178 (1.69%) 3	
Vascular disorders			
Aneurysm subjects affected / exposed occurrences (all)	18 / 177 (10.17%) 21	11 / 178 (6.18%) 13	
Hypotension subjects affected / exposed occurrences (all)	14 / 177 (7.91%) 17	8 / 178 (4.49%) 8	
Steal syndrome subjects affected / exposed occurrences (all)	16 / 177 (9.04%) 16	9 / 178 (5.06%) 11	
Subclavian vein stenosis subjects affected / exposed occurrences (all)	9 / 177 (5.08%) 10	7 / 178 (3.93%) 12	
Vascular stenosis subjects affected / exposed occurrences (all)	124 / 177 (70.06%) 608	104 / 178 (58.43%) 313	
Venous stenosis subjects affected / exposed occurrences (all)	18 / 177 (10.17%) 21	21 / 178 (11.80%) 42	
Nervous system disorders			

Hypoaesthesia subjects affected / exposed occurrences (all)	7 / 177 (3.95%) 7	14 / 178 (7.87%) 15	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	12 / 177 (6.78%) 13	10 / 178 (5.62%) 11	
General disorders and administration site conditions Implant site extravasation subjects affected / exposed occurrences (all) Oedema peripheral subjects affected / exposed occurrences (all) Peripheral swelling subjects affected / exposed occurrences (all)	11 / 177 (6.21%) 12 9 / 177 (5.08%) 10 13 / 177 (7.34%) 15	11 / 178 (6.18%) 14 14 / 178 (7.87%) 15 8 / 178 (4.49%) 8	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	14 / 177 (7.91%) 16 12 / 177 (6.78%) 18 13 / 177 (7.34%) 18	10 / 178 (5.62%) 13 14 / 178 (7.87%) 15 9 / 178 (5.06%) 11	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	13 / 177 (7.34%) 17	7 / 178 (3.93%) 8	
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	7 / 177 (3.95%) 7	9 / 178 (5.06%) 9	
Infections and infestations			

Pneumonia			
subjects affected / exposed	10 / 177 (5.65%)	6 / 178 (3.37%)	
occurrences (all)	12	6	
Upper respiratory tract infection			
subjects affected / exposed	8 / 177 (4.52%)	11 / 178 (6.18%)	
occurrences (all)	8	11	
Urinary tract infection			
subjects affected / exposed	14 / 177 (7.91%)	11 / 178 (6.18%)	
occurrences (all)	18	13	
Vascular access site infection			
subjects affected / exposed	6 / 177 (3.39%)	13 / 178 (7.30%)	
occurrences (all)	7	15	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	6 / 177 (3.39%)	9 / 178 (5.06%)	
occurrences (all)	7	11	
Hyperkalaemia			
subjects affected / exposed	9 / 177 (5.08%)	19 / 178 (10.67%)	
occurrences (all)	6	23	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 November 2016	<p>The first protocol version under which subjects were enrolled was protocol Version 3.0.</p> <p>Amendment No. 3 leading to protocol Version 4.0</p> <ul style="list-style-type: none">• Clarified that Inclusion Criterion 7 required meeting both of the following criteria:<ul style="list-style-type: none">– ≤ 2x upper limit of normal for serum bilirubin, aspartate transaminase and alanine transaminase– ≤ 1.5 for international normalized ratio or prothrombin time ≤ 18 seconds unless the subject was taking an anticoagulant at the time• Removed consideration of alkaline phosphatase levels.• Clarified Exclusion Criterion 9 that excluded subjects with active clinically significant immune-mediated disease, not controlled by maintenance immunosuppression.• Added details on recommended antithrombotic prophylaxis. Specifically, that aspirin was the antiplatelet therapy of choice and that anticoagulation was contraindicated without a specific medical need.• Allowed serum as well as urine pregnancy tests at screening.• Clarified what constituted abandonment to match the definition stated in the clinical events committee charter. The change defined abandonment as no remaining segment of the study conduit was incorporated into the vascular access circuit used for dialysis.• Clarified that subjects were to have 1 dose (versus 1 day) of antibiotic prophylaxis in accordance with local institutional guidelines.• Clarified that intraoperative heparin was not required and could be administered at the discretion of the Investigator.• Clarified that AEs were to be collected beginning on Day 0 after implantation.• Deleted reference to randomization block size to avoid any potential bias at randomization.• Clarified that the safety analysis was to be carried out in the safety population (defined as all subjects who received study treatment, with the subject's treatment group based on the treatment that was received) and not on the intent-to-treat population.

08 August 2018	<p>Amendment No. 4 leading to protocol Version 5.0</p> <ul style="list-style-type: none"> • Clarified exclusion criterion #7 with the following details: <ul style="list-style-type: none"> – Low dose glucocorticoid therapy (e.g. up to 10 mg a day prednisone or prednisolone) was acceptable. – High dose glucocorticoid therapy for treatment of autoimmune flare, or other inflammatory diseases was excluded. – Subjects using glucocorticoids for immunosuppression post-transplant to prevent against transplanted allograft rejection in the period post allograft failure were to be excluded. – The following examples of immunosuppressive agents (or the like) were exclusionary for enrollment in this clinical trial: tacrolimus or FK506 (Prograf), mycophenolate mofetil (Cellcept), cyclosporine (Sandimmune or Gengraf), Sirolimus administered systemically (sirolimus in drug eluting stents was not an exclusion). • Revised the timing of the primary analysis to be conducted when all subjects were at least 18 months post-implantation (or had a prior censoring event). • Clarified that freedom from spontaneous rupture of the study conduit was the main safety concern and that damage from iatrogenic injuries was to be considered an AE. • Added steal syndrome to list of Events of Special Interest. • Clarified that extension to the screening period for scheduling delays was allowed with medical monitor approval. • Clarified that panel reactive antibodies samples should be drawn prior to transplant for any subjects who received a kidney transplant during the study. • Clarified that the visit window for visits from Month 30 to Month 60 was ± 1 month. • Clarified that subjects withdrawn prior to Month 24 were to complete an early termination (ET) visit that correlated with the procedures at Month 24. Subjects withdrawn after Month 24 and prior to Month 60 were to complete an ET visit that correlated with procedures post Month 24 through Month 60.
----------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Pre-specified original analysis (time-to-event analysis; Cox proportional hazard test) was underpowered for this study. Posthoc binary analysis of event-free rates of secondary patency was found to be appropriate for original study design and power.

Notes: